December 23, 2016
TiGenix submits Day 120 Responses to EMA for Crohn`s disease drug
TiGenix has submitted its responses to the European Medicines Agency`s (EMA) Day 120 List of Questions for Cx601, its lead…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 23, 2016
AstraZeneca, Pfizer complete more than a billion dollars worth antibiotics sale agreement
AstraZeneca has sold to Pfizer the commercialization and development rights of its late-stage small molecule antibiotics business, comprising the approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development.
December 23, 2016
Xbrane names new strategic advisor, aims to boost its leading products
Xbrane Biopharma has named Anders P. Wiklund as strategic advisor. He presently serves on the boards of EffRx Pharmaceuticals SA, Inspirion Delivery Technologies LLC, Life Medical AB and IRRAS AB.
December 23, 2016
Roche’s haemophilia drug reduces number of bleeds, study shows
Roche’s phase III study of haemophilia drug emicizumab prophylacis for 12 yearolds and older has met its primary endpoint, as…
December 23, 2016
FMR LLC shareholding in Ablynx slightly increases
Ablynx has received a notification of shareholdings from FMR LLC, according to which its stake in Ablynx has slightly increased.
December 22, 2016
ImmuPharma recruits patients for Phase III study of Lupuzor
ImmuPharma has completed patients recruitment regarding pivotal Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough…
December 22, 2016
Biocartis submits 510(k) to FDA, expands European hospitals deal with Amgen
Biocartis has today strenghten its collaboration with two companies; J&J’s Jansen and Amgen, as it has submitted 510(k) its diagnostics…
December 22, 2016
Abzena in licence agreement with USA-based Trieza
Abzena has granted USA-based Trieza an exclusive worldwide, royalty bearing, sub-licensable licence to an undisclosed antibody sequence, for exploitation in…
December 22, 2016
Advanced Oncotherapy happy with technical development of the LIGHT system
Advanced Oncotherapy has successfully tested and calibrated programme at ADAM in Geneva, and that made it possible to integrate the…
December 22, 2016
Horizon’s lung infections antibiotic Quinsair available in Canada for adults with Cystic Fibrosis
Horizon Pharma and its Canadian affiliate Horizon Therapeutics Canada Limited have brought its inhalation solution for chrnic lung infection Quinsair to Canada.
Quinsair is used for chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF).